The study aims to improve the already rapid time-to-result of INBS's drug screening technology, which collects samples in under a minute and provides results within ten minutes at the point of collection. Faster results will enable INBS to target the global roadside drug testing market with a first-in-class solution.

In the U.S. alone, roadside drug testing was valued at $1.17 billion in 2023 and is projected to reach $1.62 billion by 2030, growing at a compound annual growth rate of 4.71%1. The rise in prescription medications, recreational marijuana, and illicit drugs has created a surge in drug-related accidents and fatalities. Law enforcement agencies are intensifying efforts to combat impaired driving, creating demand for advanced testing solutions that deliver quick, accurate field results. INBS's system is already deployed in the Forensic Use Only market in the U.S., and enhanced speed would further strengthen the technology's positioning as states expand drug testing programs following marijuana legalization and increased substance abuse concerns.

Faster analysis times have the potential to transform roadside drug testing in the same way that breathalyzers revolutionized alcohol enforcement. Increased testing throughput will enable law enforcement to screen more drivers, improving road safety and potentially saving lives. In addition to roadside applications, accelerated testing would further expand INBS's access to other high-value verticals beyond its established workplace testing business, which currently operates outside the United States, including drug treatment and rehabilitation, and the consumer health market.

The wider global drug screening products market is projected to grow at a compound annual growth rate of approximately 14% through 2030, reaching an estimated addressable market of $16.7 billion2. Time-to-result is increasingly valued as law enforcement and government agencies favor fast, non-invasive, point-of-collection solutions that are easy to administer.

INBS continues to navigate the regulatory pathway and remains focused on securing FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening System for detection of the opiate codeine, which will enable broader use in the U.S. market beyond current Forensic Use Only settings. The U.S. market represents a multi-billion-dollar opportunity spanning workplace testing, criminal justice, law enforcement, and substance abuse treatment and enhanced testing speed would provide a compelling competitive advantage as the Company pursues planned U.S. market entry.

The validation study is in its preliminary phase.